|
 |
|||||
|
|||||
|
|
|
 
Dr. Orlandi’s experience in drug development spans over twenty years, ranging from early to late development and commercialization, with a main focus on late stage, Phase 3 Clinical work. Over this period of time, he has been responsible for the development, submission, and regulatory approval of several compounds in the cardiovascular area. Prior to joining Cardiokine, Dr. Orlandi was Vice President, Global Clinical Development at Otsuka Pharmaceuticals where he was responsible for a variety of programs including tolvaptan, a vasopressin receptor antagonist. He has also held the Vice President, Research & Development position with Medco Research, Inc., in Research Triangle Park, NC; Medical Director and Principal Investigator, Nuclear Cardiology positions with The DuPont Merck Pharmaceutical Company in North Billerica, MA; and was a visiting scientist with the Upjohn Company in Kalamazoo, MI. Dr. Orlandi received his M.D. with honors from the University of Pavia Medical School, Pavia, Italy. He is licensed and board certified in cardiology in Italy, where he served as Staff Physician in the Department of Internal Medicine, Ospedale S. Matteo and University of Pavia Medical School, Pavia, Italy. Dr. Orlandi has also held academic and hospital appointments at Harvard Medical School and Brigham and Women's Hospital in Boston, MA. He maintains an Assistant Professor of Medicine position at Tufts University School of Medicine, in Boston, MA. He is a Fellow of the American College of Cardiology, the European Society of Cardiology, and a member of numerous other professional societies. He has also published an extensive number of original articles, reviews, books, and abstracts. Anthony Durning Mr. Durning has over 20 years experience in pharmaceutical product development and manufacturing. He joined CardioKine as Vice President, Manufacturing in August 2004. Mr. Durning was most recently Vice President, Manufacturing Operations for Eximias Pharmaceutical Corporation where he was responsible for all aspects of Chemistry Manufacturing and Controls. Prior to that he was responsible for global parenteral clinical supplies manufacturing for RPR. Mr. Durning also worked at the Liposome Company for 14 years where his role evolved from managing process development to being responsible for plant management and the manufacturing launch of the company's first commercial drug, Abelcet. He began his career at Enzo Biochem and has also managed a clinical manufacturing facility for Bristol-Myers Squibb. Mr. Durning received his BS from Rutgers University .
Mr. LaBella brings over 20years experience to Cardiokine. He joined in September 2004 and has held various executive positions in research and development, regulatory affairs, and clinical trial operations. He was most recently the Vice President of Phase IV Clinical Operations at Pharmanet where he was also a member of the Executive Committee. His many accomplishments include a history of numerous successful NDA submissions and approvals; managing, directing and building corporate development efforts to the point of merger and acquisition; and the co-developer of a patented novel pharmaceutical dosage form. He has also served on the Board of Directors at Somerset Pharmaceuticals. He began his career at Sandoz Pharmaceuticals in project management and regulatory affairs. Mr. LaBella received his undergraduate degree in pharmacy from the University of Connecticut and his graduate degree from the Arnold and Marie Schwartz College of Pharmacy and Health Sciences.
Ms. O’Brien joined Cardiokine in April 2005 bringing 25 years of diverse financial experience working with emerging growth companies, as well as public companies, primarily in the pharmaceutical and technology industries. Ms. O’Brien’s experience includes operational, merger and acquisitions, financing, initial public offerings, financial reporting, and public company compliance. From January, 2003 to April 2005, Ms. O’Brien was the Corporate Controller at Barrier Therapeutics, Inc (BTRX), a specialty pharmaceutical company focused on dermatology. Ms. O’Brien was part of the working group which took Barrier public in May 2004. During 2001 and 2002, Ms. O’Brien provided strategic chief financial officer support and guidance to growth companies holding interim and part-time CFO positions at a number of early stage venture-backed companies. In 1996, Ms. O'Brien joined Infonautics, Inc as the Director of Finance, following Infonautics’ initial public offering. Ms. O'Brien was named Vice President, Chief Financial Officer, and Treasurer in 1999. From 1994 to 1996 Ms. O'Brien was a Business Assurance Manager with Coopers & Lybrand L.L.P. Ms. O’Brien holds a Bachelor of Arts degree from Rutgers University and she is a Certified Public Accountant.
Mr. Selihar brings a wealth of experience in the industry and an extensive background in strategic marketing and commercial development to Cardiokine. Most recently, Len held the position of Vice President, Early Commercial Input and Emerging Franchises with the Pharmaceuticals Group Strategic Marketing of Johnson and Johnson. In that capacity, he was responsible for leading commercial assessments of potential licensing candidates and as a member of the Drug Evaluation Management Team he was charged with providing commercial input to R&D for early stage compounds across a variety of therapeutic areas. Prior to joining JNJ, Len held numerous positions of increasing responsibility during his 30 years in the industry at Pfizer/Pharmacia, GlaxoSmithKline, and Merck & Co. Inc. At Pharmacia, as Vice President, Commercial Development, Len was a key member of the Primary Care Development and Global Patent committees. Len was responsible for Global Strategic Marketing and commercial input to Licensing for Cardiovascular and Metabolic Products at GSK and while at Merck, Len held positions in field sales, Canadian and US line Marketing, Marketing Communications for MSD AgVet, and Global Strategic Marketing where he led the Worldwide introductions of Mevacor, Zocor and Proscar. |
 |
 |
